Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.
Type:
Grant
Filed:
November 17, 2015
Date of Patent:
May 30, 2023
Assignee:
Biohaven Therapeutics Ltd.
Inventors:
Vladimir Coric, Robert Berman, Ronald S. Vladyka, Amgad Saleh, Danny Yu
Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (referred to herein as “BHBA-001”), which, inter alia, is a (selective) retinoic acid receptor beta (RAR?) (e.g., RAR?2) agonist. The present invention also pertains to pharmaceutical compositions comprising such crystalline forms, and the use of such crystalline forms and compositions, both in vitro and in vivo, to (selectively) activate RAR? (e.g., RAR?2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR? (e.g., RAR?2), that are ameliorated by the activation of RAR? (e.g., RAR?2), etc., including, e.g., neurological injuries such as spinal cord injuries.
Type:
Grant
Filed:
December 2, 2020
Date of Patent:
February 21, 2023
Assignee:
King's College London
Inventors:
Ronnie Maxwell Lawrence, Edwin Aret, Alan David Borthwick, Jane Theresa Brown, Jonathan Patrick Thomas Corcoran, Maria Beatriz De Castro Vasconcelos Goncalves, Sarkis Barrett Kalindjian
Abstract: The present invention includes a solid lyophilized form of 2-(4-Methyl-[1,4]diazepan-1-yl)-5-oxo-5H-7-thia-1,11b-diaza-benzo[c]fluorene-6-carboxylic acid (5-methyl-pyrazin-2-ylmethyl)-amide (Compound I) and the process of producing the solid lyophilized form. Furthermore, the present invention provides compositions comprising Compound I, or a pharmaceutically acceptable salt and/or solvate thereof and therapeutic use of the composition.
Abstract: Pharmaceutical or nutraceutical formulations are provided for treating inflammation in a subject in need thereof, as well as methods of treating inflammation in a subject in need thereof by administering one of the formulations. In some aspects, the pharmaceutical or nutraceutical formulation includes an effective amount of (i) palmitoylethanolamide or a derivative thereof, and (ii) one, two, three or more different small-molecule polyphenols or derivatives thereof to alleviate one or more causes or symptoms of the inflammation in the subject. In some aspects, the formulations include all three, e.g. the formulations includes (i) palmitoylethanolamide or a derivative thereof, (ii) quercetin or a derivative thereof, and (iii) curcumin or a derivative thereof. In some instances, the components (i)-(iii) discussed above are present at a mass ratio of about (i) 4 mg to 6 mg of palmitoylethanolamide or a derivative thereof to (ii) about 0.5 to 2.5 mg curcumin or a derivative thereof, and (iii) about 0.5 mg to 1.
Type:
Grant
Filed:
June 14, 2019
Date of Patent:
December 13, 2022
Assignees:
The Texas A&M University System, Core Vibe Health Inc.
Inventors:
Susanne U. Mertens-Talcott, Ariela Betsy Thomas, Vinicius De Paula Venancio, Geoffrey R. Pfeifer, Blake M. Ebersole
Abstract: Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a ?2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.
Abstract: A nanosuspension comprising (a) a pharmaceutical active ingredient or nutraceutical active ingredient having low solubility; (b) at least one alginate selected from the group consisting of (i) sodium alginate having a viscosity of 100 mPa·s or less in a 1% solution in water at 20° C. and (ii) potassium alginate; and (c) water. Also, a drug dosage form prepared from such a nanosuspension.
Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.
Abstract: Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist.
Type:
Grant
Filed:
August 31, 2020
Date of Patent:
November 8, 2022
Assignee:
CARDIX Therapeutics, LLC
Inventors:
Jin Jean Wang, Gerald J. Yakatan, Ting N. Lin, Jing H. Gao
Abstract: Described herein is the use of Adelmidrol in the treatment of epithelial dysfunctions. In particular, described herein is Adelmidrol for use in the treatment of epithelial tissue dysfunctions in a human being or animal, wherein said Adelmidrol causes an increase of the endogenous levels of Palmitoylethanolamide without inhibiting the activity of the Palmitoylethanolamide-degrading FAAH and NAAA enzymes.
Type:
Grant
Filed:
April 4, 2019
Date of Patent:
November 8, 2022
Assignee:
Epitech Group S.p.A.
Inventors:
Maria Federica Della Valle, Francesco Della Valle, Vincenzo Di Marzo, Stefania Petrosino, Barbara Costa, Gabriele Marcolongo, Daniele Grassi
Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.
Type:
Grant
Filed:
October 26, 2016
Date of Patent:
September 20, 2022
Assignee:
DEL MAR PHARMACEUTICALS (BC) LTD.
Inventors:
Jeffrey A. Bacha, Dennis M. Brown, Anne Steinø
Abstract: This invention is announcing a composition of flavonoid skeleton in the formula I or formula II compound, wherein each of the substituents is given the definition as set forth in the specification and claims. This composition has the capacity to treating or preventing a virus infection in a subject.
Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
Type:
Grant
Filed:
June 5, 2018
Date of Patent:
August 9, 2022
Assignee:
PTC THERAPEUTICS, INC.
Inventors:
Matthew G. Woll, Lukiana Amedzo, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Anthony R. Mazzotti, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Zhenrong Xu
Abstract: Solid pharmaceutical dosage forms comprising (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate (telotristat) are disclosed, as well as methods of making them and compositions useful in their manufacture.
Type:
Grant
Filed:
November 19, 2019
Date of Patent:
August 9, 2022
Assignee:
TerSera Therapeutics LLC
Inventors:
Jinling Chen, Matthew S. Deaver, Richard J. Holl, Kalyan Nuguru
Abstract: The present invention relates to a method of controlling abiotic stress on warm-season turfgrass using an effective amount of acibenzolar-s-methyl.
Abstract: The present disclosure relates to a 1-(4-benzyloxy-benzyl)-3-methyl-thiourea compound in crystalline forms A, B, C, or amorphous form, a method for preparing the compound in the crystalline or amorphous forms, and a use of the compound for preventing or treating a metabolic disease or inflammatory disease.
Type:
Grant
Filed:
November 26, 2019
Date of Patent:
July 19, 2022
Assignees:
Therasid Bioscience Inc., Seoul National University R&DB Foundation
Inventors:
Wooyoung Kwak, Sungki Seo, Heung Jae Kim
Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
Type:
Grant
Filed:
November 7, 2019
Date of Patent:
July 12, 2022
Assignee:
SYDNEXIS, INC.
Inventors:
Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
Abstract: The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.
Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.
Type:
Grant
Filed:
July 30, 2018
Date of Patent:
June 14, 2022
Assignees:
STERO BIOTECHS LTD., MOR RESEARCH APPLICATIONS LTD.